ALACHUA, Fla.–(BUSINESS WIRE)–Today, Montagu Private Equity LLP (‘Montagu’), a leading European private equity firm, announced the completion of its acquisition of the RTI Surgical OEM business. Following the acquisition, the OEM business will operate as a standalone company and retain the RTI Surgical name.
The new RTI Surgical will further its focus on driving innovation across its tissue, biologics and hardware platforms and strengthening its long standing collaboration with leading medical technology companies. The company will continue to distribute a comprehensive portfolio of surgical implants across multiple segments and commercial channels.
Olivier Visa, who has led the OEM business since 2017 will serve as President and Chief Executive Officer of RTI Surgical. “Today, with the support of Montagu, we are launching a new RTI Surgical, focused on employee development, customer intimacy and patient-centric innovation. Our service mindset will fuel our partnerships across all segments and channels we serve, deepening relationships with our customers and distributors to accelerate growth, serve more patients and maximize the gift of tissue donation. Montagu’s support, combined with our talented team, will unlock tremendous value for our existing and future partners. This is an inflexion point in our history that leverages the strength and resilience of our OEM business. Our future is supported by strong market trends toward increased outsourcing for industry leading design, development, processing and manufacturing services. We are tremendously thankful for the support from our partners, employees and distributors whose dedication and support have made this transition a very positive one,” Visa said.
Guillaume Jabalot, Director at Montagu, said: “As a strong, resilient business that is well-positioned to capitalize on accelerated growth opportunities, the OEM business is an excellent fit for Montagu’s investment strategy. We share a similar ambition for sustainable growth and look forward to working with Olivier and the team to support the business in this exciting next chapter, maintaining its ethos of exceptional service and innovation.”
About RTI Surgical
RTI Surgical (RTI) is a global, industry leading surgical implant supplier that provides design, new product development, processing and manufacturing services in support of patients and leading medical technology companies. With expertise spanning tissue, biologics and hardware, we serve OEM partners across a diverse set of market segments, including but not limited to, Dental, Plastic and Reconstructive Surgery, Sports Medicine, Spine, Trauma and Urology/Urogynecology. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, visit www.rtisurgical.com.
About Montagu
Montagu Private Equity is one of Europe’s leading private equity firms and has been investing in businesses for over fifty years. Montagu’s investment strategy is focused on partnership with management in buyouts of high-quality companies operating in stable and growing sectors, providing products and services that their customers would badly miss. It develops a shared strategic vision with management and then provides the necessary financial, strategic and operational resources to help realize that vision and support growth. Montagu partners with companies with enterprise values between €200 million and €1 billion and has raised over €8bn in the last 10 years. RTI Surgical is Montagu’s 23rd corporate carve-out since 2002. For additional information on Montagu, visit www.montagu.com.
Contacts
Amelia Bell, APR, CPRC
Marketing & Communications
Phone (386) 418-8888
abell@rtix.com
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting…
MINNEAPOLIS, June 21, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the…
Shrivers Hospice sets a benchmark for quality care in Ohio with prestigious award LOS ANGELES,…